Risperidone (Risperdal) is the medication most clearly associated with neutropenia among the options listed.
Among risperidone, valproic acid (Depakote), trazodone, and prazosin, risperidone carries the most direct risk of neutropenia, though valproic acid can significantly increase this risk when combined with other medications.
Evidence Hierarchy
The FDA drug label for Risperdal explicitly warns about leukopenia, neutropenia, and agranulocytosis 1. The label states that patients with a history of clinically significant low white blood cell count (WBC) or drug-induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy, and discontinuation should be considered at the first sign of clinically significant WBC decline 1.
Clinical practice guidelines confirm that while agranulocytosis is primarily associated with clozapine, it can occur with any antipsychotic agent 2. Specifically, there is documented evidence of leukocytopenia in a teenage boy receiving risperidone 2.
Clinical Evidence Supporting Risperidone-Induced Neutropenia
Research demonstrates that risperidone can cause severe neutropenia. A 2021 case report documented a patient who developed severe neutropenia after just two weeks of oral risperidone treatment, with neutrophil levels returning to normal after discontinuation 3. A prospective study found neutropenia (neutrophils <2,000/μL) occurred in 17.6% of patients receiving second-generation antipsychotics other than clozapine over six months 4.
Valproic Acid as a Contributing Factor
Valproic acid (Depakote) does not directly cause neutropenia as a primary effect, but it significantly potentiates neutropenia risk when combined with antipsychotics. Multiple studies demonstrate this interaction:
- The combination of valproate with antipsychotics and ADHD medications increased neutropenia incidence to 55.2% versus 25% with valproate-antipsychotic combination alone 5
- Valproate combined with quetiapine increased neutropenia risk 3.75-fold (odds ratio 3.749,95% CI 1.161-12.099) 6
- A case report documented clozapine-associated neutropenia that commenced specifically after adding sodium valproate 7
Other Medications
Trazodone and prazosin are not associated with neutropenia. The evidence provided discusses trazodone only in the context of serotonin syndrome 8, with no mention of hematologic effects. Prazosin does not appear in any neutropenia-related evidence.
Clinical Monitoring Recommendations
For patients on risperidone, particularly those with risk factors:
- Monitor complete blood count frequently during the first few months of therapy 1
- Exercise heightened vigilance when combining with valproic acid, as this dramatically increases neutropenia risk 7, 5, 6
- Consider discontinuation at the first sign of clinically significant WBC decline in the absence of other causative factors 1
- Be aware that neutropenia is typically transient and resolves with medication discontinuation 3, 4
Critical Caveat
When valproic acid is co-prescribed with risperidone or other antipsychotics, the risk of neutropenia increases substantially beyond either medication alone. This interaction should prompt more frequent monitoring and lower threshold for intervention.